Innoviva, Inc. (INVA) has a MoatMap StockRank of 98/100 based on Quality (76/100), Value (65/100), and Momentum (55/100) factor scores. The current signal is STRONG BUY. Innoviva is an asset-light royalty company in the healthcare sector, generating predictable cash flows from developed drugs. This model is a prime example of a quality compounder with high ROIC and pricing power. In an environment of 'Higher-for-Longer Rates', its robust free cash flow and low debt provide significant resilience and appeal, as it is less reliant on cheap capital and its defensive sector offers stability. The market may be underpricing the defensive strength and consistent, asset-light FCF generation of such royalty models in a volatile, higher-rate environment. [BUYBACK TAILWIND: Active buyback (SEC): $5M repurchased (ending 2025-12-31)] [BUYBACK TAILWIND: Active buyback (SEC): $5M repurchased (ending 2025-12-31)] [BUYBACK TAILWIND: Active buyback (SEC): $20M repurchased (ending 2026-03-31)]
Innoviva, Inc. focuses on royalties from respiratory drugs, primarily through its collaboration with GlaxoSmithKline (GSK) on therapies like Relvar/Breo Ellipta and Anoro Ellipta. The company benefits from a stable, long-term revenue stream derived from royalties on blockbuster respiratory medications, minimizing operational and R&D expenditures. It is a unique healthcare company acting primarily as a royalty aggregator, providing exposure to established drug franchises.
| Price | $22.46 |
| Market Cap | $1.7B |
| P/E (TTM) | 3.47 |
| P/E (Forward) | 9.83 |
| Price/Book | 1.20 |
| Return on Equity | 50.7% |
| Return on Invested Capital | 21.7% |
| Debt/Equity | 24.70 |
| Gross Margin | 74.1% |
| Operating Margin | 40.1% |
| Revenue Growth | 10.6% |
| Free Cash Flow | $105M |
Innoviva, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).